先声药业(02096)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02096 先声药业

未开盘 10-16 16:08:16

11.020

+0.190

+1.75%

最高11.290	最低10.850	成交量580.10万
今开10.850	昨收10.830	日振幅4.06%
总市值282.99亿	流通市值282.99亿	总股本25.68亿
成交额6,399万	换手率0.23%	流通股本25.68亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02096","market":"HK","secType":"STK","nameCN":"先声药业","latestPrice":11.02,"timestamp":1792138096002,"preClose":10.83,"halted":0,"volume":5801000,"delay":0,"changeRate":0.01754385964912276,"floatShares":2568000000,"shares":2568000000,"eps":0.54,"marketStatus":"未开盘","change":0.19,"latestTime":"10-16 16:08:16","open":10.85,"high":11.29,"low":10.85,"amount":63994681,"amplitude":0.040628,"askPrice":11.02,"askSize":35000,"bidPrice":10.98,"bidSize":3000,"shortable":3,"etf":0,"ttmEps":0.703662,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792459800000},"marketStatusCode":0,"adr":0,"listingDate":1603728000000,"exchange":"SEHK","adjPreClose":10.83,"dividendRate":0.019177,"openAndCloseTimeList":[[1792114200000,1792123200000],[1792126800000,1792137600000]],"volumeRatio":1.6397923702353228,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02096","defaultTab":"news","newsList":[{"id":"2675593659","title":"先声药业任晋生，被时代冷落的大佬","url":"https://stock-news.laohu8.com/highlight/detail?id=2675593659","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675593659?lang=zh_cn&edition=full","pubTime":"2026-10-16 17:52","pubTimestamp":1792144329,"startTime":"0","endTime":"0","summary":"被时代冷落，有时不是因为不努力。1995年，江苏先声药业正式成立。但任晋生的眼光，没有停在\"卖药赚钱\"上。那年4月20日，先声药业登陆纽交所，募资2.61亿美元，成为第一家登陆纽交所的中国化学生物制药企业。任晋生，是那个孤独的先行者。任晋生选的，是多点开花、分散风险的开放生态。任命一公布，就掀起了合规争议。2026年8月，任晋生重新兼任CEO。先声的尴尬在于，它总比时代快半","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1792120311600840862","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1191","BK1583","02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120025391","title":"先声药业10月13日回购142.8万股股份，总额约1,534.31万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1120025391","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120025391?lang=zh_cn&edition=full","pubTime":"2026-10-13 18:26","pubTimestamp":1791887186,"startTime":"0","endTime":"0","summary":"先声药业集团有限公司于2026年10月13日发布公告，披露当日于香港联交所场内回购股份事宜。此次回购行为与公司既定的股份回购计划相关。根据公告，公司于2026年10月13日回购普通股142.8万股，占回购前已发行股本的约0.056%。回购价格介乎每股10.54港元至10.82港元，合计耗资约1,534.31万港元。公告显示，先声药业的股份回购授权于2026年6月12日获得股东大会通过，授权可回购的股份数量上限为256,819,861股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"先声药业10月13日回购142.8万股股份，总额约1,534.31万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675631353","title":"先声药业(02096)10月13日斥资1534.31万港元回购142.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2675631353","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675631353?lang=zh_cn&edition=full","pubTime":"2026-10-13 18:24","pubTimestamp":1791887075,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先声药业(02096)发布公告，该公司于2026年10月13日斥资1534.31万港元回购142.8万股股份，每股回购价格为10.5438-10.82港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1506577.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02096","BK1191","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674852162","title":"先声药业(02096)回购再加码：斥资1737万港元回购，传递长期发展积极信号","url":"https://stock-news.laohu8.com/highlight/detail?id=2674852162","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674852162?lang=zh_cn&edition=full","pubTime":"2026-10-09 21:21","pubTimestamp":1791552092,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，10月9日，先声药业宣布，斥资1736.989万港元回购159.8万股。业绩端，先声药业创新药转型成效持续兑现。9月初，先声药业旗下抗肿瘤创新药公司先声再明宣布，与罗氏就SIM0660达成全球独家授权，取得7500万美元首付款、14.55亿美元里程碑及最高至双位数的分级销售提成。截至目前，先声药业集团已完成6项对外授权，潜在总交易金额超61亿美元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505471.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02096","BK1191","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674150852","title":"先声药业(02096.HK)回购再加码：斥资1737万港元回购，传递长期发展积极信号","url":"https://stock-news.laohu8.com/highlight/detail?id=2674150852","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674150852?lang=zh_cn&edition=full","pubTime":"2026-10-09 21:21","pubTimestamp":1791552092,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","02096","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125806700","title":"先声药业10月9日回购159.8万股，耗资约1,736.99万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1125806700","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125806700?lang=zh_cn&edition=full","pubTime":"2026-10-09 18:17","pubTimestamp":1791541020,"startTime":"0","endTime":"0","summary":"先声药业集团有限公司于2026年10月9日发布翌日披露报表，宣布于当日在香港联交所场内回购普通股159.8万股，约占此前已发行股本的0.062%。本次回购股份的每股价格介乎10.66港元至11.003港元，合计耗资约1,736.99万港元。回购完成后，公司已发行股本维持为2,568,198,618股，尚无库存股份。公司于2026年6月12日获得回购授权，可回购股份总数为256,819,861股。截至目前，先声药业已通过香港联交所或其他证券交易所合计回购6,441,000股，占该回购授权通过当日公司已发行股本的2.51%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"先声药业10月9日回购159.8万股，耗资约1,736.99万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674853301","title":"先声药业(02096)10月9日斥资1736.99万港元回购159.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2674853301","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674853301?lang=zh_cn&edition=full","pubTime":"2026-10-09 18:13","pubTimestamp":1791540783,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先声药业(02096)发布公告，于2026年10月9日，该公司斥资1736.99万港元回购159.8万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505309.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02096","BK1191","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132938588","title":"先声药业9月股份维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1132938588","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132938588?lang=zh_cn&edition=full","pubTime":"2026-10-05 16:37","pubTimestamp":1791189433,"startTime":"0","endTime":"0","summary":"先声药业于2026年10月5日发布截至2026年9月30日的证券变动月报表。公司全称为先声药业集团有限公司，报告显示公司在本月内尚未发生新的股份发行或注销，已发行股份总数维持在2,568,198,618股，库存股份数为0股。目前先声药业普通股最低公众持股量门槛为15.45%，公司已确认其符合相关公众持股量要求。先声药业确认将继续遵守香港联交所《上市规则》及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671222183","title":"港股异动 | 先声药业(02096)早盘涨超4% SIM0660近期授权罗氏 TCE平台价值再获验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2671222183","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671222183?lang=zh_cn&edition=full","pubTime":"2026-09-30 11:43","pubTimestamp":1790739830,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，先声药业早盘涨超4%。截至发稿，涨4.31%，报11.86港元，成交额3772.12万港元。消息面上，9月初，先声药业旗下抗肿瘤创新药公司先声再明宣布，与罗氏就SIM0660达成全球独家授权，取得7500万美元首付款、14.55亿美元里程碑及最高至双位数的分级销售提成。华泰证券发布研报称，SIM0660为全球FIC，与罗氏在B细胞疾病领域现有管线具备高度配合潜力，有望借助罗氏的全球开发及商业化体系逐步兑现全球价值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK4588","02096","KCAI","BK1583","BK4585","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117251743","title":"先声药业2026年中期营收45.80亿元，经调整净利润9.64亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1117251743","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117251743?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:40","pubTimestamp":1790239217,"startTime":"0","endTime":"0","summary":"先声药业公布2026年中期报告，报告期内营收45.80亿元人民币，同比上涨27.8%。经调整净利润9.64亿元人民币，同比提升48.7%。经营活动所得现金净额为16.05亿元，上年同期8.63亿元，增幅为85.9%。从主要治疗领域来看，神经科学领域收入20.09亿元，占比约43.9%，同比增长60.9%；抗肿瘤领域收入9.25亿元，占比20.2%，同比增长5.8%；自身免疫领域收入12.10亿元，占比26.4%，同比增长20.2%；其他业务收入4.36亿元，占比9.5%，同比增长37.8%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"先声药业2026年中期营收45.80亿元，经调整净利润9.64亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669103169","title":"【券商聚焦】兴业证券维持先声药业（02096）增持评级 指创新药高增推动盈利提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2669103169","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669103169?lang=zh_cn&edition=full","pubTime":"2026-09-23 15:12","pubTimestamp":1790147547,"startTime":"0","endTime":"0","summary":"2026年上半年，公司实现收入45.80亿元人民币，归母净利润8.29亿元人民币，经调整归母净利润9.64亿元人民币；创新药业务收入38.87亿元人民币，占总收入84.9%。神经科学收入20.09亿元人民币，占比43.9%；自身免疫收入12.10亿元人民币，占比26.4%；肿瘤领域收入9.25亿元人民币。该交易达成后，先声药业累计完成6项对外授权，潜在总交易金额超过61亿美元。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992285","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","06978","601377","KCE","LNGR","02096","IBBQ","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669017165","title":"先声药业周云曙：对外授权是阶段性选择，未来不再简单追求数量","url":"https://stock-news.laohu8.com/highlight/detail?id=2669017165","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669017165?lang=zh_cn&edition=full","pubTime":"2026-09-23 10:23","pubTimestamp":1790130233,"startTime":"0","endTime":"0","summary":"国产创新药出海BD（对外授权）交易火热，“卖青苗”争议随之而来，部分本土企业将早期管线海外权益提前授权给跨国药企，这种模式可以分担研发风险、验证中国创新价值，却也存在优质资产价值被低估的隐忧。如何兼顾短期生存与长期产业收益，成为中国创新药企出海需要权衡的命题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609233882254548.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609233882254548.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2097828714.EUR","LU1146622755.USD","LU2097828557.USD","LU1969619763.USD","LU1328615791.USD","LU0405327494.USD","LU1997245094.SGD","LU2488822045.USD","LU1997244956.HKD","LU1064131003.USD","LU1580142542.USD","BK0239","LU2580892789.USD","LU2097828805.USD","LU1064130708.USD","600276","BK0196","BK0060","LU1655091616.SGD","LU2580892862.HKD","BK0183","LU1997245177.USD","LU2097828474.EUR","LU2097828631.EUR","BK1191","BK0012","LU2328871848.SGD","LU2148510915.USD","LU0405327148.USD","BK0028","BK1583","LU2289578879.USD","BK0188","02096","LU1781817850.SGD","LU1255011170.USD","LU1820825898.SGD","LU2495084118.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669096130","title":"【券商聚焦】浙商证券维持先声药业（02096）买入评级 指创新药与BD共同兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2669096130","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669096130?lang=zh_cn&edition=full","pubTime":"2026-09-21 14:15","pubTimestamp":1789971349,"startTime":"0","endTime":"0","summary":"金吾财讯 | 浙商证券发布研报指，先声药业 2026H1业绩收入利润双高增，创新药与BD共同兑现，TCE资产再次授权。2026年上半年营业收入45.80亿元人民币，同比增长27.8%；归母净利润8.29亿元人民币，同比增长37.9%。经营活动现金净流入16.05亿元人民币，同比增长约86.0%。对外授权方面，截至2026H1，公司已就五项自主研发创新药物与国际药企达成合作，交易总金额超过46亿美元；2026H1确认许可收入4.05亿元人民币，上年同期1.22亿元人民币。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992106","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","LNGR","MEDX","159992","02096","IBBQ","601878","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154544158","title":"先声药业回购159.6万股股份，总额约1771.11万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1154544158","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154544158?lang=zh_cn&edition=full","pubTime":"2026-09-14 18:01","pubTimestamp":1789380064,"startTime":"0","endTime":"0","summary":"先声药业集团有限公司于2026年9月14日发布公告，披露其于2026年9月11日于香港联交所回购159.6万股普通股，回购价格介乎每股10.98港元至11.20港元，合计支付约1771.11万港元。本次回购股份占2026年9月10日已发行股本约0.062%。公司表示，截至2026年9月11日，已发行股本维持在25.68亿股，库藏股数为0股。先声药业集团有限公司确认，本次回购已严格遵守香港联合交易所有限公司证券上市规则及相关法律法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"先声药业回购159.6万股股份，总额约1771.11万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142091667","title":"先声药业9月11日回购159.6万股，耗资约1,771.11万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1142091667","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142091667?lang=zh_cn&edition=full","pubTime":"2026-09-11 18:25","pubTimestamp":1789122350,"startTime":"0","endTime":"0","summary":"先声药业集团有限公司于2026年9月11日公告，公司于香港联合交易所场内回购普通股1,596,000股，占该公司当日现有已发行股本的约0.062%。本次回购每股价格介乎港币10.98元至11.20元之间，合计支付的总金额为约1,771.11万港元。回购完成后，公司已发行股本总数暂维持为2,568,198,618股。公告显示，先声药业集团有限公司股东已于2026年6月12日通过购回授权，授权公司可回购股份总数达256,819,861股。本公告由先声药业集团有限公司联席公司秘书朱达签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"先声药业9月11日回购159.6万股，耗资约1,771.11万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666560799","title":"先声药业(02096)再斥资近1500万港元回购 长期主义为市场注入信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2666560799","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666560799?lang=zh_cn&edition=full","pubTime":"2026-09-10 19:22","pubTimestamp":1789039323,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，9月10日，先声药业继续回购股份，继昨日回购92.9万股后，公司再度斥资约1424.53万港元回购126.5万股，回购价格区间在11.17至11.38港元。公司的持续动作，彰显了对股东权益的重视，以及公司坚持长期主义发展的信心。2026年上半年，公司交出了一份亮眼成绩单：总营收45.8亿元，同比增长27.8%；经调整净利润9.6亿元，同比增长48.7%；创新药收入占比攀升至85%，产品和研发能力已得到认可。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02096","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134400235","title":"先声药业：9月10日回购126.50万股，耗资约1,424.53万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1134400235","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134400235?lang=zh_cn&edition=full","pubTime":"2026-09-10 18:46","pubTimestamp":1789037177,"startTime":"0","endTime":"0","summary":"先声药业集团有限公司于2026年9月10日发布公告，披露公司当日在香港联交所场内回购股份事宜。本次股份回购数量为1,265,000股，约占公司现有已发行股本的0.049%。每股最高回购价为港币11.38元，最低回购价为港币11.17元，合计支付金额约港币14,245,250元。公告显示，截至2026年9月10日，公司已发行股本仍保持2,568,198,618股不变，已回购的上述股份尚未被注销。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"先声药业：9月10日回购126.50万股，耗资约1,424.53万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666923567","title":"先声药业(02096.HK)9月10日斥资约1424.53万港元回购126.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666923567","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666923567?lang=zh_cn&edition=full","pubTime":"2026-09-10 18:44","pubTimestamp":1789037097,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1583","02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144157808","title":"先声药业：9月9日回购92.90万股，耗资约1070.33万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1144157808","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144157808?lang=zh_cn&edition=full","pubTime":"2026-09-09 18:16","pubTimestamp":1788949019,"startTime":"0","endTime":"0","summary":"先声药业集团有限公司于2026年9月9日公告，公司当日于香港联交所场内回购普通股92.90万股，占紧接该变动前已发行股本约0.036%。回购价格区间为每股港币11.48元至11.554元，合计支付约1070.33万港元。本次回购股份尚未注销，故公司已发行股本仍维持约25.68亿股，库藏股数量为0。公司另披露，购回授权于2026年6月12日获股东大会通过，可回购股份总数为256,819,861股，截至当日已回购股份总数达1,982,000股，占购回授权通过当日已发行股本约0.77%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"先声药业：9月9日回购92.90万股，耗资约1070.33万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666924584","title":"先声药业(02096)9月9日斥资1070.33万港元回购92.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666924584","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666924584?lang=zh_cn&edition=full","pubTime":"2026-09-09 18:15","pubTimestamp":1788948948,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先声药业(02096)发布公告，于2026年9月9日，该公司斥资1070.33万港元回购92.9万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1583","02096"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.simcere.com","stockEarnings":[{"period":"1week","weight":0.0119},{"period":"1month","weight":-0.0134},{"period":"3month","weight":-0.1261},{"period":"6month","weight":-0.1839},{"period":"1year","weight":-0.1323},{"period":"ytd","weight":-0.0598}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.0153},{"period":"6month","weight":-0.0754},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":-0.0563}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"先声药业集团有限公司是一家从事药品的研发、生产和销售的公司。该公司的主要产品为仿制药，包括用于中枢神经系统疾病的产品必存、用于肿瘤疾病的产品捷百舒和捷佰立、以及用于自身免疫疾病的产品英太青。该公司还从事生产创新药，比如用于肿瘤疾病的恩度。该公司还从事为医疗机构销售的第三方药品提供推广服务。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.09318},{"month":2,"riseRate":0.666667,"avgChangeRate":0.070754},{"month":3,"riseRate":0.5,"avgChangeRate":-0.014037},{"month":4,"riseRate":0.5,"avgChangeRate":-0.003707},{"month":5,"riseRate":0.666667,"avgChangeRate":0.105952},{"month":6,"riseRate":0.666667,"avgChangeRate":0.032044},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.001102},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.059624},{"month":9,"riseRate":0.5,"avgChangeRate":-0.015742},{"month":10,"riseRate":0.666667,"avgChangeRate":0.078945},{"month":11,"riseRate":0.666667,"avgChangeRate":0.044296},{"month":12,"riseRate":0.5,"avgChangeRate":0.000556}],"exchange":"SEHK","name":"先声药业","nameEN":"SIMCERE PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"先声药业(02096)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供先声药业(02096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"先声药业,02096,先声药业股票,先声药业股票老虎,先声药业股票老虎国际,先声药业行情,先声药业股票行情,先声药业股价,先声药业股市,先声药业股票价格,先声药业股票交易,先声药业股票购买,先声药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"先声药业(02096)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供先声药业(02096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}